{"id":"W2112121482","doi":"10.1016/s1470-2045(15)70076-8","title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2666,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Open label; Medicine; Nivolumab; Oncology; Chemotherapy; Internal medicine; Ipilimumab; Randomized controlled trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}